Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma

被引:2
|
作者
Subtirelu, Robert C. [1 ]
Teichner, Eric M. [2 ]
Ashok, Arjun [2 ]
Parikh, Chitra [2 ]
Talasila, Sahithi [2 ]
Matache, Irina-Mihaela [3 ]
Alnemri, Ahab G. [1 ]
Anderson, Victoria [2 ]
Shahid, Osmaan [1 ]
Mannam, Sricharvi [1 ]
Lee, Andrew [1 ]
Werner, Thomas [1 ]
Revheim, Mona-Elisabeth [4 ,5 ]
Alavi, Abass [1 ]
机构
[1] Hosp Univ Penn, Dept Radiol, Philadelphia, PA USA
[2] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA
[3] Carol Davila Univ Med & Pharm, Dept Physiol, Fac Med, Bucharest, Romania
[4] Oslo Univ Hosp, Div Orthoped Surg, Oslo, Norway
[5] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway
来源
FRONTIERS IN NEUROLOGY | 2023年 / 14卷
关键词
glioblastoma; dendritic cell vaccination; positron emission tomography; antigen loading; immunotherapy; CYTOTOXIC T-LYMPHOCYTES; MALIGNANT GLIOMA; TUMOR-ANTIGEN; BRAIN-TUMOR; FDG-PET; MULTIFORME; VACCINES; IMMUNOTHERAPY; RESPONSES; SURVIVAL;
D O I
10.3389/fneur.2023.1271822
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glioblastomas (GBM) are highly invasive, malignant primary brain tumors. The overall prognosis is poor, and management of GBMs remains a formidable challenge, necessitating novel therapeutic strategies such as dendritic cell vaccinations (DCVs). While many early clinical trials demonstrate an induction of an antitumoral immune response, outcomes are mixed and dependent on numerous factors that vary between trials. Optimization of DCVs is essential; the selection of GBM-specific antigens and the utilization of 18F-fludeoxyglucose Positron Emission Tomography (FDG-PET) may add significant value and ultimately improve outcomes for patients undergoing treatment for glioblastoma. This review provides an overview of the mechanism of DCV, assesses previous clinical trials, and discusses future strategies for the integration of DCV into glioblastoma treatment protocols. To conclude, the review discusses challenges associated with the use of DCVs and highlights the potential of integrating DCV with standard therapies.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
    Yang, Liu
    Guo, Geng
    Niu, Xiao-yuan
    Liu, Jing
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [32] Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination
    Glass, Joshua J.
    Kent, Stephen J.
    De Rose, Robert
    EXPERT REVIEW OF VACCINES, 2016, 15 (06) : 719 - 729
  • [33] PROTEIN MICROARRAY ANALYSIS OF GLIOBLASTOMA PATIENT SERA BEFORE AND AFTER DENDRITIC CELL VACCINATION
    Tucker, Alexander
    Everson, Richard
    Orpilla, Joey
    Soto, Horacio
    Yuan, Frank
    Liau, Linda
    Prins, Robert
    NEURO-ONCOLOGY, 2016, 18 : 25 - 25
  • [34] Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
    Van Gool, Stefaan W.
    Makalowski, Jennifer
    Kampers, Linde F. C.
    Van de Vliet, Peter
    Sprenger, Tobias
    Schirrmacher, Volker
    Stucker, Wilfried
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (08) : 2224 - 2228
  • [35] Pharmacological regulation of dendritic cell activation: Enhancing cancer vaccine efficacy
    Hanks, BA
    Jiang, JH
    Spencer, DM
    MOLECULAR THERAPY, 2004, 9 : S132 - S133
  • [36] In situ dendritic cell vaccination for the treatment of glioma and literature review
    Li, Ming
    Han, Shuangyin
    Shi, Xiwen
    TUMOR BIOLOGY, 2016, 37 (02) : 1797 - 1801
  • [37] Optimizing dendritic cell-based therapies for the treatment of mantle cell lymphoma
    Munger, Corey M.
    Vose, Julie M.
    Weisenburger, Dennis D.
    Kuszynski, Charles K.
    Joshi, Shantaram S.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S258 - S258
  • [38] Optimizing dendritic cell production and characterization of immune phenotype in patients with newly diagnosed or recurrent glioblastoma
    New, Kent
    Gustafson, Michael
    Bulur, Peggy
    Steinmetz, Susan
    Sprau, Debra
    O'Neill, Brian
    Dietz, Allen
    NEURO-ONCOLOGY, 2007, 9 (04) : 508 - 508
  • [39] Understanding the Murine Cutaneous Dendritic Cell Network to Improve Intradermal Vaccination Strategies
    Ginhoux, F.
    Ng, L. G.
    Merad, M.
    INTRADERMAL IMMUNIZATION, 2012, 351 : 1 - 24
  • [40] Dendritic-cell- and peptide-based vaccination strategies for glioma Comments
    Roth, Patrick
    Weller, Michael
    NEUROSURGICAL REVIEW, 2009, 32 (03) : 273 - 273